







Solo 2 ENGOT-OV21

Study of OLoparib in Ovarian Cancer

A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy





















Final Global Recruitment



ARCAGY - GINECO

